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Abstract
Background:  Mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2), two members of the
secretoglobin superfamily, are known to be co-expressed in breast cancer, where their proteins
form a covalent complex. Based on the relatively high tissue-specific expression pattern, it has been
proposed that the mammaglobin A protein and/or its complex with lipophilin B could be used in
breast cancer diagnosis and treatment. In view of these clinical implications, the aim of the present
study was to analyze the expression of both genes in a large panel of human solid tumors (n = 309),
corresponding normal tissues (n = 309) and cell lines (n = 11), in order to evaluate their tissue
specific expression and co-expression pattern.
Methods: For gene and protein expression analyses, northern blot, dot blot hybridization of
matched tumor/normal arrays (cancer profiling arrays), quantitative RT-PCR, non-radioisotopic
RNA in situ hybridization and immunohistochemistry were used.
Results:  Cancer profiling array data demonstrated that mammaglobin A and lipophilin B
expression is not restricted to normal and malignant breast tissue. Both genes were abundantly
expressed in tumors of the female genital tract, i.e. endometrial, ovarian and cervical cancer. In
these four tissues the expression pattern of mammaglobin A and lipophilin B was highly concordant,
with both genes being down-, up- or not regulated in the same tissue samples. In breast tissue,
mammaglobin A expression was down-regulated in 49% and up-regulated in 12% of breast tumor
specimens compared with matching normal tissues, while lipophilin B was down-regulated in 59%
and up-regulated in 3% of cases. In endometrial tissue, expression of mammaglobin A and lipophilin
B was clearly up-regulated in tumors (47% and 49% respectively). Both genes exhibited down-
regulation in 22% of endometrial tumors. The only exceptions to this concordance of
mammaglobin A/lipophilin B expression were normal and malignant tissues of prostate and kidney,
where only lipophilin B was abundantly expressed and mammaglobin A was entirely absent. RNA
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in situ hybridization and immunohistochemistry confirmed expression of mammaglobin A on a
cellular level in endometrial and cervical cancer and their corresponding normal tissues.
Conclusion: Altogether, these data suggest that expression of mammaglobin A and lipophilin B
might be controlled in different tissues by the same regulatory transcriptional mechanisms.
Diagnostic assays based on mammaglobin A expression and/or the mammaglobin A/lipophilin B
complex appear to be less specific for breast cancer, but with a broader spectrum of potential
applications, which includes gynecologic malignancies.
Background
Mammaglobin A (secretoglobin, family 2A, member 2 –
SCGB2A2) and lipophilin B (secretoglobin, family 1D,
member 2 – SCGB1D2) are members of the secretoglobin
superfamily, a group of small, secretory, rarely glyco-
sylated, dimeric proteins with unclear physiologic func-
tions, mainly expressed in mucosal tissues [1,2]. The
rabbit uteroglobin is the founder member of this family of
mammalian proteins [1], which has expanded to more
than 25 members in recent years, currently including nine
human secretoglobins. Mammaglobin A, lipophilin B,
and most of the human secretoglobins are localized on
chromosome 11q13, where they form a dense cluster [1].
The mammaglobin A gene (SCGB2A2) encodes a 93-
amino acid protein with a predicted molecular mass of
10.5 kDa [3,4]. In breast tissue it exists in two main forms
with approximate molecular masses of 18 and 25 kDa,
due to posttranslational modifications [5]. Mamma-
globin A is considered to be a highly specific breast tissue
marker; initially it was found to be overexpressed in breast
cancer, and its expression was restricted to normal and
malignant breast tissue [3,4]. No gene amplification or
gene rearrangement was detected in tumors overexpress-
ing mammaglobin A, suggesting changes in transcrip-
tional regulation as the cause of overexpression [4]. In
contrast to other members of the secretoglobin family [6],
its expression does not appear to be influenced by steroid
hormones [4,7].
Due to its tissue specificity, mammaglobin A has drawn
much attention with more than 70 relevant publications
in the last five years. More than 30 studies have evaluated
its role in detection of minimal residual disease in breast
cancer patients, while others investigated its role as a diag-
nostic and prognostic marker, and its potential use as a
therapeutic target (see Ref. 8 for review). Recently how-
ever, some studies have shown that it is also expressed in
tissues other than the breast [7,9-14]. In breast cancer
mammaglobin A is overexpressed in a high proportion of
primary tumors [7,14-17], and it is associated with estro-
gen receptor positive tumors, a less aggressive tumor phe-
notype [7,14,15,17], and relapse-free survival [7].
Lipophilin B (SCGB1D2) has not been studied as exten-
sively as mammaglobin A. The secreted lipophilins A, B,
and C should not be confused with the family of lipophi-
lins described as hydrophobic integral membrane pro-
teins in myelin [1]. Lipophilin B is expressed in a high
proportion of breast carcinomas [14,18], it is more fre-
quently expressed in estrogen receptor positive tumors
[14], but it shows a lower degree of tissue-specificity [18].
Recently, two studies independently showed that in breast
cancer the mammaglobin A and lipophilin B proteins
form a covalent complex, and that the two proteins are
bonded in a head-to-tail orientation [19,20]. Moreover,
the expression levels of mammaglobin A in breast tumors
were significantly correlated with those of lipophilin B
[14,19,20].
The association between mammaglobin A and lipophilin
B in breast cancer, the controversy about tissue-specificity
of mammaglobin A, and the clinical implications by the
use of both genes in cancer early detection, diagnosis, and
treatment gave us the impetus to systematically analyse
their expression in a large panel of normal and malignant
human tissues and cell lines. We report herein that mam-
maglobin A expression and its co-expression with lipophi-
lin B are not restricted to breast cancer, and that their
applications in cancer diagnosis and treatment could also
include malignancies of the female genital tract.
Methods
Tissue specimens and cell lines
Formalin-fixed paraffin-embedded tissue from cervical,
endometrial and breast cancer and corresponding normal
tissue specimens were obtained from patients treated at
the Gynecology Departments of the Charité Berlin and the
University Hospital of Aachen, with institutional review
board approval. Cell lines were obtained from ATCC and
cultured as described in the ATCC cell biology catalogue
(LGC Promochem, Teddington, England). The following
11 cell lines were analyzed by RT-PCR: HaCat (human
keratinocytes), MCF-10A (breast tissue, fibrocystic dis-
ease), T47D (breast cancer), ZR75.1 (breast cancer),
MDA-MB 468 (breast cancer), MDA-MB 231 (breast can-
cer), PC3 (prostate cancer), LnCaP (prostate cancer), DU
145 (prostate cancer), MaTu (breast cancer), and A375
(malignant melanoma).BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
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Multiple tissue northern blot in malignant and normal 
breast tissue
Mammaglobin A and lipophilin B expression was ana-
lyzed on a Clontech (Heidelberg, Germany) multiple tis-
sue northern blot containing four pairs of invasive ductal
carcinoma and matched normal tissue from four female
patients (51, 36, 47, and 45 years old). Hybridization was
performed as described in the following section for the
tumor/normal cDNA arrays.
Expression analysis using tumor/normal cDNA arrays
Mammaglobin A and lipophilin B expression were each
analyzed using two different nylon filter arrays from Clon-
tech (Heidelberg, Germany), each containing spotted
cDNAs from tumor and corresponding normal tissue of
the same patient. The "Matched Tumor/Normal Expres-
sion Array" (MTNA) (Clontech, Product number 7840)
consisted of 136 cDNAs, synthesized from 68 tumor and
68 matched normal tissue specimens. The "Cancer Profil-
ing Array" (CPA) (Clontech, Product number 7841) con-
sisted of 511 dots with 494 cDNAs synthesized from 241
primary tumor, 241 matched normal tissue, and 12
cDNAs from metastases corresponding to 12 of the
tumor/normal pairs. Each cDNA pair was independently
normalized based on the expression of housekeeping
genes used as controls and immobilized in separate dots
[22]. Data for controls and clinicopathological parame-
ters for each specimen can be found on the provider's
website [23,24].
For both the MTNA and CPA, hybridization was per-
formed using 25 ng of a gene-specific 32P-labeled cDNA
probe derived from Unigene cDNA clones (SCGB2A2:
AA513640;  SCGB1D2: AJ224172). These gene-specific
cDNA fragments were radiolabelled using a Megaprime
labelling kit (Amersham Biosciences, Braunschweig, Ger-
many), hybridized overnight at 68°C using ExpressHyb
Hybridization Solution (Clontech, Heidelberg, Ger-
many), washed, and exposed to Kodak XAR-5 X-ray film
with an intensifying screen (Eastman Kodak Co, Roches-
ter, NY, USA). The tumor/normal intensity ratio was cal-
culated using a Typhoon 9410 High Performance Imager
(GE-Healthcare, Chalfont St. Giles, UK) and normalized
against the background.
The specificity of the mammaglobin A and lipophilin B
hybridization probes was determined by co-hybridization
of nylon membranes containing different concentrations
of spotted mammaglobin A and lipophilin B cDNAs in
plasmid clones: 1 ng, 100 pg, 10 pg and 1 pg of cDNA
from each gene were diluted in 100 ul of 15XSSC buffer,
heat-denatured for 5 min by boiling and then quenched
on ice. Denatured cDNAs were spotted on Hybond N+
membranes (Amersham Biosciences, Freiburg, Germany)
using a vacuum manifold (Millipore, Eschborn, Ger-
many). These membranes were treated during filter
hybridization, washing and exposition exactly like the
tumor/normal arrays
Quantitative RT-PCR
Mammaglobin A and lipophilin B expression were ana-
lyzed with real-time RT-PCR in a panel of 11 cell lines (see
above) and 23 normal human tissues (see Figures 5 and
6) using commercially available RNA (Clontech, Heidel-
berg, Germany). For each cDNA synthesis, 1µg of RNA
was reverse transcribed using the Superscript II Reverse
Transcription System (Invitrogen, Karlsruhe, Germany),
according to the instructions of the manufacturer.
Real-time RT-PCR was performed with the Gen Amp®
5700 sequence detection system (PE Applied Biosystems,
Weiterstadt, Germany), using intron-spanning primers
and FAM (5' end)/TAMRA (3' end) – labeled specific oli-
gonucleotides. The housekeeping gene GAPDH was used
as reference. Primers and probes used in this study are pre-
sented in Table 1. Each PCR reaction was performed in a
Table 1: Primers and probes used in real-time RT-PCR
Gene Primer sequence Product size
SCGB2A2 5'-GAACACCGACAGCAGCA-3'
5'-TCTCCAATAAGGGGCAGCC-3'
104 bp
SCGB1D2 5'-CTGAGCTCACAGCAAAAC -3'
5'-GAGCTGGGCAGAAC-3'
105 bp
GAPDH 5'-GAAGGTGAAGGTCGGAGTC-3'
5'-GAAGATGGTGATGGGATTTC-3'
226 bp
Gene TaqMan probe
SCGB2A2 5'-TGGTCCTCATGCTGGCGGCC-3'
SCGB1D2 5'-CCATGAAGCTGTCGGTGTGTCTCCTG-3'
GAPDH 5'-CAAGCTTCCCGTTCTCAGCC-3'BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
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25µl volume, which included 12.5µl 2XTaqMan Univer-
sal PCR-Mastermix (PE Applied Biosystems, Weiterstadt,
Germany), 1 ng of cDNA template, 300 nM of forward
and 900 nM of reverse primer, and the specific probe for
each gene (150 nM for mammaglobin A and 100 nM for
lipophilin B). Gene expression was quantified by the com-
parative CT method, normalizing CT-values to the house-
keeping gene GAPDH  and calculating the relative
expression values of tumor and normal tissues [21].
Non-radioisotopic RNA in situ hybridization
Non-radioisotopic RNA in situ hybridization in cervical
and endometrial cancer and matched normal tissue was
performed as previously described [25].
Immunohistochemistry
Formalin-fixed paraffin embedded tissue was freshly cut
(4µm). The sections were mounted on superfrost slides
(Menzel Gläser, Braunschweig, Germany), deparaffinized
with xylene and gradually hydrated. We used a mono-
clonal anti-mammaglobin A antibody (BioPrime, NY,
USA, MAM001-05, dilution 1:100). Antigen retrieval for
mammaglobin A was achieved by heat and citrate buffer
using the Ventana immunostainer and all slides were
stained with the BenchMark® XT autostainer (Ventana,
Tucson AZ, USA).
Results
Expression analysis using multiple tissue northern blots
Mammaglobin A (SCGB2A2) and lipophilin B
(SCGB1D2) expression was analyzed by northern blot in
a panel of 4 matched breast cancer/normal breast tissue
pairs (Figure 1). Transcripts of approximately 600 bp in
size for both genes were expressed in the same two out of
four tumor samples, with hybridization signals of similar
intensity in each sample (compare Figure 1A with Figure
1B).
Expression analysis using Cancer Profiling Arrays (CPAs)
Mammaglobin A (SCGB2A2) and lipophilin B
(SCGB1D2) expression were analyzed by dot blot analysis
using Clontech's "Matched Tumor/Normal Array"
(MTNA) and "Cancer Profiling Array I" (CPA) for each
gene. The two expression arrays together contained 630
cDNAs synthesized from 309 human tumor and 309
matched normal tissue specimens, and 12 cDNAs from
human metastases corresponding to 12 of the tumor/nor-
mal pairs. The specificity of the mammaglobin A and
lipophilin B hybridizations on the arrays was established
by co-hybridization of two dot blots, containing spotted
plasmid cDNAs of either mammaglobin A or lipophilin B
(see Figure 2). The radiolabelled mammaglobin A probe
efficiently hybridized only to mammaglobin A cDNA (not
Abundant (co)expression of mammaglobin A (SCGB2A2) (1A) and lipophilin B (SCGB1D2) (1B) in breast tumors Figure 1
Abundant (co)expression of mammaglobin A (SCGB2A2) (1A) and lipophilin B (SCGB1D2) (1B) in breast 
tumors. Gene expression was determined using a Clontech tumor/normal northern blot (see Materials and Methods). The 
two genes were expressed in the same tumors, with similar hybridization signal intensities. IDC: Invasive Ductal Carcinoma; N: 
Normal breast tissue.BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
Page 5 of 13
(page number not for citation purposes)
to lipophilin B cDNA), and it was detectable up to a con-
centration of 1 pg. Likewise, the radiolabelled lipophilin
B probe efficiently hybridized only to lipophilin B cDNA,
and it was detectable up to a concentration of 10 pg. Thus,
cross-hybridization was excluded between the two related
genes of the secretoglobin family.
Overall, abundant expression of at least one of the two
genes was detected in six of the 13 tested primary tumor
entities and corresponding normal tissues. These results
are summarized in Table 2. Mammaglobin A expression
was abundant in malignant and normal samples from the
breast (Figure 2A), uterus (Figure 2C), ovaries (Figure 2E)
and uterine cervix (Figure 2G), and absent in the majority
of samples from the other nine tissues (prostate, kidney,
colon, rectum, small intestine, stomach, pancreas, lung,
and thyroid). In the small number of metastatic samples
tested its expression was heterogeneous (Figure 2). Mam-
maglobin A expression was also detectable in one out of
25 gastric, one out of 24 lung, one out of 34 kidney, and
two out of 25 rectal tumors, but not in the corresponding
normal samples (data not shown). As in the case of mam-
maglobin A, lipophilin B expression was abundant in
malignant and normal samples from the breast (Figure
2B), uterus (Figure 2D), ovaries (Figure 2F) and uterine
cervix (Figure 2H). In addition, abundant lipophilin B
Mammaglobin A and lipophilin B (co)expression in breast and gynecologic tumors and matched normal samples Figure 2
Mammaglobin A and lipophilin B (co)expression in breast and gynecologic tumors and matched normal sam-
ples. Expression profiles were determined using two different Clontech cancer profiling arrays for each gene (see Methods). 
Mammaglobin A and lipophilin B expression were each analyzed in 59 matched breast tumor/normal samples (Figures 2A and 
2B), 49 matched uterine (Figures 2C and 2D), 18 matched ovarian (Figures 2E and 2F), two matched samples from the uterine 
cervix (Figures 2G and 2H), as well as in nine further tumor entities (data not shown). Rows N represent normal tissue, and 
rows T represent tumor. The outlined groups of three dots represent normal tissue (breast N: -G,  -I, -K, uterus N: -V, -Z, and 
ovary N: -I, -K), primary tumor (breast T:  -G, -I, -K, uterus T: -V, -Z, and ovary T: -I, -K), and metastases (breast  T: -H, -J, -L, 
uterus T: -W, -AA, and ovary T: -J, -L) from the same  patient. Control dots (labeled MG and LipB, respectively) were  co-
hybridized in order to confirm the specificity of mammaglobin A and  lipophilin B probes (see results).BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
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expression was found in matched samples from the kid-
ney and the prostate (Table 2), while it was absent in most
samples from the other seven tissues. Lipophilin B expres-
sion was also detectable in one out of 25 gastric, one out
of 24 lung, and two out of 25 rectal tumors, but not in the
corresponding normal samples (data not shown).
The expression pattern of mammaglobin A in malignant
and normal samples from different tissues was in general
highly concordant to that of lipophilin B (compare e.g.
Figure 2A and 2B for breast tissue), except for kidney and
prostate samples, where only lipophilin B but not mam-
maglobin A was expressed. The two genes exhibited an
identical pattern of differential expression (i.e. both
down-, up- or non-regulation) in the majority of matched
pairs from the breast (78%), uterus (78%), ovaries (56%),
and the uterine cervix (100%) (Table 2), without marked
disparities (i.e. no cases with one gene up- and the other
down-regulated) in the remaining cases. According to the
Spearman rank correlation test, co-expression of mamma-
globin A and lipophilin B was highly significant in breast,
uterine and ovarian tissues (each p < 0.001) but failed to
reach significance in cervical tissues due to the small sam-
ple size (n = 2). A very interesting finding was that mam-
maglobin A and lipophilin B were both up-regulated in
the same one out of 25 gastric, and the same two out of 25
rectal tumor samples, in which expression of the two
genes was detectable. However, this was not the case with
lung tumors, in which mammaglobin A and lipophilin B
were each expressed in one out of 24, but not in the same
sample (data not shown). No correlation was found
between the (co)expression pattern of mammaglobin A
and lipophilin B in various tumors and available clinico-
pathological data.
Quantitative RT-PCR
Mammaglobin A (SCGB2A2) and lipophilin B
(SCGB1D2) expression were analyzed with real-time RT-
PCR in a panel of 11 cell lines and 23 normal human tis-
sues using commercially available RNA (Clontech, Hei-
delberg, Germany). Among the cell lines tested,
mammaglobin A was expressed only in the breast cancer
cell line ZR-75.1, and negative in the other five breast and
five non breast cell lines (Figure 3). Lipophilin B was
expressed in the same cell line, as well as in the T-47D
(breast cancer cell line) and LnCaP cells (prostate cancer
cell line)(Figure 4). There was no major difference in
expression of both genes between tumor cells grown
under confluent and subconfluent conditions.
Among all normal tissues tested, mammaglobin A expres-
sion was highest in normal tissue from the uterine cervix,
followed in descending order by normal breast tissue, thy-
mus, uterus, testis, trachea, and stomach. No mamma-
globin A expression was detected in the other 16 normal
tissues (Figure 5). As with mammaglobin A, lipophilin B
expression was highest in normal tissue from the uterine
cervix. Lipophilin B was also expressed in descending
order in the uterus, breast, kidney, colon, pancreas, heart,
placenta, and testis. There was no detectable lipophilin B
expression in the other 14 normal tissues (Figure 6).
Non-radioisotopic RNA in situ hybridization and 
immunohistochemistry
In order to further establish the expression of mamma-
globin A in gynecologic malignancies, we have analyzed
its expression in tissue sections from cervical and endome-
trial cancer and normal tissue using non-radioisotopic
RNA in situ hybridization. Consistently with the dot blot
hybridization and quantitative RT-PCR results presented
above, mammaglobin A was expressed in normal cervical
glands (Figure 7A) as well as in cervical and endometrial
cancer (Figure 7 D, G). Representative sections are pre-
sented in Figure 7. Furthermore we performed immuno-
histochemistry using a mammaglobin A-specific antibody
(BioPrime, NY, USA,) on paraffin-embedded tissue from
Table 2: Mammaglobin A and lipophilin B (co)expression data from cDNA dot blots
Mammaglobin A regulation * Lipophilin B regulation * Concordance of expression
Tissue type n (total) up down- no up- down- no
n % n%n%n % n%n%
Breast 59 7 12% 29 49% 23 39% 2 3% 35 59% 22 38% Yes (78%)
Uterus 49 23 47% 11 22% 15 31% 24 49% 11 22% 14 29% Yes (78%)
Ovary 18 5 28% 3 17% 10 55% 4 22% 6 33% 8 45% Yes (56%)
Cervix 2 2 100% 0 0% 0 0% 2 100% 0 0% 0 0% Yes (100%)
Kidney 34 1 3% 0 0% 0 0% 1 3% 16 47% 17 50% No
Prostate 7 n.e. n.e. n.e. 0 0% 2 29% 5 71% No
n.e.: not expressed
* The percentage of up-regulation (or down-regulation) was defined as follows: The number of tumor/normal tissue pairs with an at least 2-fold-up-
regulation (or down-regulation) in the tumor tissue divided by the total number of samples in this entity × 100. Fold changes between 0.5 and 2.0 
were considered as not differentially expressed ("no regulation").BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
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breast cancer, as well as cervical and endometrial cancer.
Mammaglobin A was clearly detectable in invasive ductal
(Figure 8A) and invasive lobular (Figure 8B) carcinoma of
the breast. Mammaglobin A protein was also detectable in
squamous cell carcinoma of the cervix (Figure 8C) and in
endometrioid adenocarcinoma of the endometrium (Fig-
ure 8D).
Discussion
In initial reports mammaglobin A appeared to be an
almost ideal tissue marker, since its expression was
restricted to normal and malignant breast tissue (see Ref.
8 for review). Subsequently, mammaglobin A was evalu-
ated for detection of minimal residual disease in breast
cancer patients [8,26,27], differential diagnosis of metas-
tases and malignant pleural effusions [26-29], and as an
immunotherapeutic target in in vitro experiments [30-33]
and  in vivo animal models [34,35]. However, in later
reports, its expression was detected, rarely and/or in low
levels, in various normal and malignant tissues: the nor-
mal uterine cervix [10], uterus [9-11,36], ovary
[10,14,36], thymus, testis, trachea, skeletal muscle, kidney
[36], skin [18], sweat glands [13], salivary glands [18,36],
prostate [10], and nasal mucosa [37], and tumors of the
sweat glands [13], lungs [12] and ovaries [14].
Our results confirm that mammaglobin A is expressed in
various normal and malignant tissues other than the
breast, and thus it is rather not an ideal breast-specific
marker. Expression of mammaglobin A in normal tissues
certainly limits its potential use as an immunotherapeutic
target, due to concerns about autoimmune toxicity, partic-
ularly since autoimmunity is not a concern with other
immunotherapeutic targets [38]. Our results, also confirm
previous reports that mammaglobin A is not expressed in
all breast cancer cell lines and breast tumors
[3,4,7,14,16,39], and thus does not have a 100% sensitiv-
ity as a diagnostic marker. An important finding of our
Mammaglobin A (SCGB2A2) expression in human cell lines. Diagrammatic presentation of quantitative RT-PCR data Figure 3
Mammaglobin A (SCGB2A2) expression in human cell lines. Diagrammatic presentation of quantitative RT-
PCR data. SCGB2A2 mRNA was abundantly expressed in the tumorigenic breast cancer cell line ZR 75.1. SCGB2A2 was unde-
tectable in four breast cancer cell lines (T47D, MDA-MB 468, MDA-MB 231, MaTu), in benign breast tissue (MCF-10A), in 3 
prostate cancer cell lines (PC3, LnCaP, DU 145), in normal human keratinocytes (HaCat), and in malignant melanoma (A375). 
c: confluent growth; sc: subconfluent growth.BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
Page 8 of 13
(page number not for citation purposes)
study was that mammaglobin A is commonly expressed in
normal and malignant tissue of the female genital tract,
and only rarely or at low levels in other normal and malig-
nant tissues. It should be noted that expression in gyneco-
logic tissues was demonstrated by four independent
methods (dot blot hybridization of matched tumor/nor-
mal arrays, real time RT-PCR, non-radioisotopic RNA in
situ  hybridization and immunohistochemistry). Thus,
given the limitations in specificity and sensitivity, mam-
maglobin A could be also used in diagnostic assays for
detection of gynecologic malignancies.
The expression pattern of lipophilin B in our study, as well
as in previous reports, appeared to be even less tissue spe-
cific than that of mammaglobin A, and thus its use as a
diagnostic marker seems very unlikely. In the present
study, lipophilin B was abundantly expressed in normal
and malignant tissue from the breast, cervix, uterus, ovary,
kidney and prostate. Lower or rare lipophilin B expression
was found in normal colon, pancreas, heart, in gastric and
rectal tumors, and as previously reported in normal testis
and placenta [36] and lung tumors [12]. In previous
reports, lipophilin B expression was also detected in the
normal anterior pituitary and pituitary adenomas [40], in
normal adrenal gland, cartilage, retina, [18], skin [19],
and salivary gland [19,36].
The most important finding regarding lipophilin B expres-
sion in the present study was that it is concordant to that
of mammaglobin A in most tissues tested. It has been pre-
viously reported, that mammaglobin A and lipophilin B
are significantly co-expressed in breast cancer [14,19,20],
and their proteins are bonded in an antiparallel manner
forming a covalent complex [19,20]. In the present study
we found that their co-expression is not restricted to
breast tumors, but is also present in normal breast tissue,
as well as normal and malignant tissue from the uterus,
ovaries, and uterine cervix. On the other hand, in normal
Lipophilin B (SCGB1D2) expression in human cell lines. Diagrammatic presentation of quantitative RT-PCR data Figure 4
Lipophilin B (SCGB1D2) expression in human cell lines. Diagrammatic presentation of quantitative RT-PCR 
data. SCGB1D2 mRNA was expressed in two tumorigenic breast cancer cell lines (ZR 75.1 and T47D), as well as in one pros-
tate cancer cell line (LnCaP). SCGB1D2 was undetectable in three breast cancer cell lines (MDA-MB 468, MDA-MB 231, MaTu), 
in benign breast tissue (MCF-10A), in two prostate cancer cell lines (PC3, DU 145), in normal human keratinocytes (HaCat), 
and in malignant melanoma (A375). c: confluent growth; sc: subconfluent growth.BMC Cancer 2006, 6:88 http://www.biomedcentral.com/1471-2407/6/88
Page 9 of 13
(page number not for citation purposes)
and malignant prostate and kidney tissue lipophilin B was
abundantly expressed while mammaglobin A was entirely
absent. Interestingly, the only gastric and two rectal
tumors expressing mammaglobin A expressed lipophilin
B as well, but this was not seen in lung cancer. Altogether,
these data suggest that expression of the two genes, which
are both localized on the same cluster on chromosome
11q13, is probably regulated by common transcriptional
mechanisms. It is also reasonable to expect, that serum
antibodies against lipophilin B or against its complex with
mammaglobin A, as those previously detected in breast
cancer patients [18], could also be found in patients with
gynecologic tumors.
Conclusion
Systematic expression analysis of a panel of solid tumors
and normal tissues showed that mammaglobin A and
lipophilin B are abundantly expressed in malignant and
normal tissues of the breast and the female genital tract,
namely the cervix, uterus, and ovary, while lower expres-
sion levels were rarely found in other tumors and normal
tissues. Intriguingly, the expression pattern of the two
genes was highly concordant in most tissues tested, sug-
gesting common regulatory transcriptional mechanisms.
Use of mammaglobin A and its complex with lipophilin B
in breast cancer diagnosis might lead to less specific
results than previously expected, but these markers could
also be used in diagnosis of gynecologic cancer. The
potential use of mammaglobin A as an immunotherapeu-
tic target might be limited, due to the possibility of
autoimmune toxicity.
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